TLDR: LSD does not provide psychological resilience during stressful experiences such as job loss – and may increase psychological distress. Highlights: The study analyzed data from 5,067,553 unemployed individuals seeking jobs. LSD users who had used the drug more than a year before job loss were the focus to ensure accurate results. LSD use prior …
TLDR: GLP-1 agonists were found to significantly reduce the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) compared to DPP-4 inhibitors and sulfonylureas. Highlights: A sequential trial emulation was conducted using data from Swedish national registers from 2010 to 2020, involving 88,381 participants aged 65 or older with T2DM. The incidence …
TLDR: Occasional drinking may help reduce the risk of major depression, but frequent drinking worsens it. Highlights: Occasional alcohol consumption is linked to a lower risk of major depression. Frequent alcohol intake increases the risk of major depression. The risk increase from frequent drinking persists even when different types of alcohol are considered. The impact …
TLDR: This case study reports the highest recorded nonfatal clozapine overdose (10,000 mg) in an elderly patient, causing significant fluctuations in blood concentration levels following treatment. Highlights: A 71-year-old female ingested 10,000 mg of clozapine, significantly above typical overdose levels, leading to an initial blood concentration of 5200 μg/L. Despite initial treatment, blood clozapine levels …
TLDR: Quercetin-based alginate nanogels loaded with brain-derived neurotrophic factor (BDNF) can effectively cross the blood-brain barrier via intranasal delivery, providing a promising treatment for depressive disorders. Highlights: Nanogels: Quercetin nanogels protect BDNF from oxidative damage, exhibit rapid brain distribution, and significantly enhance bioavailability compared to oral administration. Efficacy: BDNF-Quercetin nanogels delivered via intranasal route show …
TLDR: Esketamine nasal spray, combined with standard antidepressant therapy, significantly improves remission rates and reduces time to remission in adults with major depressive disorder (MDD) and acute suicidality compared to standard care alone. Highlights: Remission Rates: Patients treated with esketamine plus standard of care had higher remission rates than those treated with placebo plus standard …
Antidepressant use has risen steadily for 30 years. Over 10% of adults in England now take them long-term, but evidence suggests up to half lack clear medical justification to continue. Patients and doctors are reluctant to stop treatment due to fears of relapse and withdrawal effects. Research indicates more proactive treatment review, slower drug tapering …
New research provides clarity on the most effective cessation aids available. Varenicline, cytisine, and e-cigarettes help the greatest proportion of people quit long-term. Slowly tapering nicotine dose before ending treatment may also boost success rates. Bupropion slightly raises the risk of serious side effects. Key Facts: Varenicline, cytisine, and e-cigarettes have the highest quit rates, …
Insomnia is a common sleep disorder affecting up to 15% of adults. While sedative medications are often prescribed, their long-term use can lead to dependence. As an alternative, antidepressants are widely used in clinical practice despite limited evidence supporting their efficacy and safety for insomnia. Key Facts: Insomnia affects up to 15% of adults, causing …
Depression is highly prevalent in older adults and those with cardiovascular disease. Selective serotonin reuptake inhibitors (SSRIs) are generally safe first-line treatments, but many wonder if they’re safe for those with cardiovascular disease. Key Facts: There is insufficient evidence to confirm the safety of most newer antidepressants for older and cardiovascular patients. SNRIs like venlafaxine …
